Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

Stocks Recover on Fed Rate Cut Expectations

View original at nasdaq.com
Stocks Recover on Fed Rate Cut Expectations The S&P 500 Index ($SPX) (SPY) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.06%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cut full-year adjusted EPS forecast to $1.94-$2.04 from previous estimate of $2.35-$2.45, well below consensus of $2.37

    80% confidence

  • Q3 earnings rose 14.6%, more than doubling expectations of 7.2% y/y

    80% confidence

  • Upgraded Vertex Pharmaceuticals to overweight from equal weight with price target of $516

    80% confidence

  • Forecasted Q4 operating income of $220 million to $230 million, above consensus of $214.5 million

    80% confidence

  • Forecasted Q4 revenue of $251 million to $252 million, midpoint below consensus of $251.9 million

    80% confidence

  • Upgraded Stellantis to buy from neutral with price target of $12

    80% confidence

  • Kevin Hassett is seen as the likely choice to succeed Powell as Fed Chair

    80% confidence

  • 83% of reporting S&P 500 companies exceeded forecasts, on course for the best quarter since 2021

    80% confidence

  • Raised 2026 comparable sales growth forecast to low single digits from previous estimate of flat

    80% confidence

  • Upgraded Astera Labs to buy with price target of $275

    80% confidence

  • Q3 adjusted EPS forecasted at 40 cents, above consensus of 37 cents

    80% confidence

  • Microsoft is reducing its AI software sales quotas amid consumer resistance to newer products

    80% confidence

  • He will announce his selection for the new Fed Chair in early 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Recover on Fed Rate Cut Expectations — Source | Via News | Finance Via News